VB4-P5 - novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney ...
5d
XORTX Therapeutics Inc.: XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
VB4-P5 - novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therape ...
Early detection of kidney disease is now possible with a simple blood test, as a protein-based risk score can predict kidney ...
Fatty liver linked to diabetes is emerging as a silent but serious complication, progressing without symptoms and affecting ...
A new blood test can identify which individuals of African ancestry carrying high-risk APOL1 gene variants are most likely to ...
The patient in the current case report showed manifestations of both AAV and IgG4-RD; his improvement linked to steroid/cyclophosphamide treatment underscores the need for integrated diagnosis and ...
Vertex Pharmaceuticals (NASDAQ: VRTX) and Mirum Pharmaceuticals (NASDAQ: MIRM) are two biotech stocks that share the same ...
A boy who received a partial liver transplant from his mother and a kidney transplant from his father within a year has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results